UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd, further expanding their strategic partnership initiated in 2021. The collaboration will focus on development, regulatory filings, and commercialization related to Claudin 18.2 concomitant diagnosis. Financial details of the agreement were not disclosed.
About Abcam
Abcam is a leading company engaged in the identification, development, and sales of high-quality biological reagents and tools. The company boasts advanced technologies such as Hybridoma, B-cell cloning, and next-generation sequencing (NGS) based platforms, as well as three RabMAb development platforms. These technologies and platforms enable abcam to provide a wide range of high-quality products and services to the scientific community.
About MEDx Translational Medicine
MEDx Translational Medicine Co., Ltd is a prominent player in the field of drug clinical transformation, concomitant diagnostics (CDx) development, and drug use guidance and testing. The company has over 20 products approved for marketing, including the first domestically approved JAK2-V617F mutation detection kit. MEDx also has a robust pipeline of more than 40 CDx/IVD products under development, with 10 currently at clinical stages. This strong product portfolio and development pipeline position MEDx as a key innovator in the diagnostics space.
Collaboration Focus
The partnership between abcam and MEDx will leverage the strengths of both companies to advance the development and commercialization of Claudin 18.2 concomitant diagnosis. This collaboration aims to accelerate the availability of diagnostic tools for Claudin 18.2, which is a promising target in the field of oncology, particularly for gastric and pancreatic cancers. By combining abcam’s expertise in biological reagents and MEDx’s capabilities in CDx development, the partnership is expected to make significant strides in bringing innovative diagnostic solutions to market.-Fineline Info & Tech
